Please select the option that best describes you:

Topics: Breast Cancer • Medical Oncology • BRCA+ • Breast Cancer, Non-metastatic

Given recent OS data from the OlympiA trial, would you offer adjuvant olaparib to a BRCA+ patient with pT1bN0 TNBC?

Ref: Geyer et al, Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec;33(12):1250-1268.

Does OS benefit compel you to try to expand your use of adjuvant olaparib?

Answer from: Medical Oncologist at Community Practice

I would not, as those patients were not included in OlympiA.

Sign in or Register to read more